Baptist Health Oncologist Co-Authors New England Journal of Medicine article

Dr. Firas Badin, MD, with Baptist Health Medical Group Hematology and Oncology, co-authored an article featured in the June 22 issue of The New England Journal of Medicine.

Dr. Firas Badin, MD, with Baptist Health Medical Group Hematology and Oncology, co-authored an article featured in the June 22 issue of The New England Journal of Medicine.  

The article, “First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer,” reported findings of a Phase III research study that compared the effectiveness of the immunotherapy drug nivolumab, which is marketed as Opdivo, with standard-of-care chemotherapy in 541 patients with previously untreated or recurrent non-small-cell lung cancer.  

Baptist Health Lexington enrolled patients in the clinical trial, and Badin served as the local principal investigator. Findings could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique characteristics of their tumor.